Jun. 24 at 10:27 AM
$TMDX
TD Cowen ups target to 170
TransMedics (NASDAQ: TMDX)
Buy (1)
ESG Score: 61/100
Price Target:
$170.00 (Prior
$146.00)
Best Smidcap Ideas: OCS/NOP/Logistics Flywheel Accelerates to a Higher Gear
THE TD COWEN INSIGHT
TMDX is poised to outperform 2Q'25, FY25, and long-range plan expectations, driven by surging U.S. demand for its integrated OCS/NOP/transplant logistics platform. Next-gen platform rollouts and pivotal heart and lung clinical programs will drive deeper adoption, new market segment penetration, and sustainable transplant preservation volume growth in 2025 and beyond. TMDX is our top smidcap pick.